As per the transaction announced on January 30, 2025, Opsy Holding AB was acquired by OPSY AB, in a reverse merger transaction. Opsy Holding AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. Opsy Holding AB was formerly known as WntResearch AB and changed its name to Opsy Holding AB in April 2025. The company was incorporated in 2007 and is based in Lund, Sweden.
Metrics to compare | OPSYH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOPSYHPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.9x | 11.8x | |
PEG Ratio | 0.00 | 0.03 | 0.01 | |
Price/Book | 0.0x | 2.3x | 2.4x | |
Price / LTM Sales | 0.0x | 1.5x | 2.2x | |
Upside (Analyst Target) | 0.0% | 103.0% | 19.0% | |
Fair Value Upside | Unlock | 21.4% | 5.6% | Unlock |